Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes

Trial ID: NCT03936829

Interventional - Phase Unknown - Active, not recruiting

This study evaluates the change of insulin resistance and glucose metabolism of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the treatment of cyclophosphamide.

Conditions

• Lipodystrophy Acquired
• Type1diabetes

Interventions

• Cyclophosphamide

Eligibility

Inclusion criteria

• 1. Meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.
• 2. Meet the diagnostic criteria for panniculitis: fat biopsy suggests inflammatory infiltration.
• 3. Meet the diagnostic criteria for acquired lipodystrophy syndrome: childhood onset, clinically no nutritional deficiency or catabolism, systemic or partial subcutaneous fat reduction, genetic testing to exclude congenital lipodystrophy syndrome; low leptin level and autoantibodies can aid in diagnosis.

Exclusion criteria

• 1. Mature and effective treatment methods are available.
• 2. HIV, HBV and HCV were positive.
• 3. A the active period of infection.
• 4. At the active stage of malignant tumors.
• 5. Combination of other fatal diseases.
• 6. Existence of mental and psychological diseases.

Sponsor

Children's Hospital of Fudan University

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows